

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Synthesis of Novel mRNA 5' Cap-Analogues: Dinucleoside P<sup>1</sup>, P<sup>3</sup>-Tri-, P<sup>1</sup>, P<sup>4</sup>-Tetra-, and P<sup>1</sup>, P<sup>5</sup>-Pentaphosphates

Jacek Jemielity<sup>a</sup>; Janusz Stepinski<sup>a</sup>; Magdalena Jaremko<sup>a</sup>; Dorota Haber<sup>a</sup>; Ryszard Stolarski<sup>a</sup>; Robert E. Rhoads<sup>b</sup>; Edward Darzynkiewicz<sup>a</sup>

<sup>a</sup> Department of Biophysics, Institute of Experimental Physics, Warsaw University, Warsaw, Poland <sup>b</sup>

Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA

Online publication date: 09 August 2003

**To cite this Article** Jemielity, Jacek , Stepinski, Janusz , Jaremko, Magdalena , Haber, Dorota , Stolarski, Ryszard , Rhoads, Robert E. and Darzynkiewicz, Edward(2003) 'Synthesis of Novel mRNA 5' Cap-Analogues: Dinucleoside P<sup>1</sup>, P<sup>3</sup>-Tri-, P<sup>1</sup>, P<sup>4</sup>-Tetra-, and P<sup>1</sup>, P<sup>5</sup>-Pentaphosphates', *Nucleosides, Nucleotides and Nucleic Acids*, 22: 5, 691 – 694

**To link to this Article:** DOI: 10.1081/NCN-120022611

**URL:** <http://dx.doi.org/10.1081/NCN-120022611>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## Synthesis of Novel mRNA 5' Cap-Analogues: Dinucleoside P<sup>1</sup>, P<sup>3</sup>-Tri-, P<sup>1</sup>, P<sup>4</sup>-Tetra-, and P<sup>1</sup>, P<sup>5</sup>-Pentaphosphates

Jacek Jemielity,<sup>1</sup> Janusz Stepinski,<sup>1</sup> Magdalena Jaremko,<sup>1</sup>  
Dorota Haber,<sup>1</sup> Ryszard Stolarski,<sup>1</sup> Robert E. Rhoads,<sup>2</sup>  
and Edward Darzynkiewicz<sup>1,\*</sup>

<sup>1</sup>Department of Biophysics, Institute of Experimental Physics,  
Warsaw University, Warsaw, Poland

<sup>2</sup>Department of Biochemistry and Molecular Biology, Louisiana State University  
Health Sciences Center, Shreveport, Louisiana, USA

### ABSTRACT


A series of new mRNA anti reverse cap analogues (ARCA) was designed to obtain a tool for studying the mechanism of protein translation. Dinucleoside P<sup>1</sup>, P<sup>3</sup>-tri-, P<sup>1</sup>, P<sup>4</sup>-tetra- and P<sup>1</sup>, P<sup>5</sup>-pentaphosphates, linked by a 5'-to-5' phosphate bridge and composed of modified 7-methylguanosine and guanosine, have been synthesized. The hydroxyl group (2'OH or 3'OH) in 7-methylguanosine moiety was replaced by -OCH<sub>3</sub> or -H in order to obtain the cap analogues capable to be correctly incorporated into synthetic mRNA transcripts. Tri-, tetra-, and pentaphosphates were prepared by ZnCl<sub>2</sub> catalyzed condensation in DMF of derivatives of the 7-methylguanosine diphosphates with the guanosine mono-, di- and triphosphate P-imidazolides, respectively. The structures of the novel compounds were established by means of <sup>1</sup>H and <sup>31</sup>P NMR spectra.

\*Correspondence: Edward Darzynkiewicz, Department of Biophysics, Institute of Experimental Physics, Warsaw University, 02-089 Warsaw, Poland; E-mail: edek@biogeo.uw.edu.pl.



## INTRODUCTION

The 5'-cap structure is present in almost all eukaryotic mRNAs. Among its several regulatory functions, cap plays an essential role in facilitating recruitment of the ribosome to the starting codon during the translation initiation.<sup>[1]</sup> This process occurs by interaction of 5'-cap with a cap binding protein, eukaryotic initiation factor 4E (eIF4E).<sup>[2]</sup> Synthetic analogues of the mRNA cap proved to be very useful in studying eIF4E function in cap-dependent translation.<sup>[3]</sup> The dinucleoside triphosphates, with their most representative member m<sup>7</sup> GpppG, are widely used in *in vitro* synthesis of 5' capped mRNAs and U snRNAs by bacteriophage RNA polymerases.<sup>[4]</sup> Such synthetic transcripts are widely applied in search for mechanisms of protein translation, RNA transport, and pre-mRNA splicing.<sup>[5]</sup> However, it was found that one-third to one-half of the cap is incorporated in the unwanted, reverse orientation, with the m<sup>7</sup> Guo moiety linked by a 3'-5' phosphodiester bond to the first nucleoside of the RNA chain.<sup>[6]</sup> Recently we synthesized two novel analogues in which 3'OH group in m<sup>7</sup> Guo was replaced by either 3'OCH<sub>3</sub> or 3'deoxy.<sup>[7]</sup> These modifications made the anti-reversed cap analogues (ARCAs) incapable of being incorporated in the reverse orientation. ARCAs retained all their inhibitory activity as compared with unmodified m<sup>7</sup> GpppG. Moreover, the translation efficiency of



Abbreviation	X	Y	n
m <sup>7</sup> 3'OMeGp <sub>3</sub> G	OH	OMe	1
m <sup>7</sup> 3'dGp <sub>3</sub> G	OH	H	1
m <sup>7</sup> 2'dGp <sub>3</sub> G	H	OH	1
m <sup>7</sup> 2'OMeGp <sub>3</sub> G	OMe	OH	1
m <sup>7</sup> 3'OMeGp <sub>4</sub> G	OH	OMe	2
m <sup>7</sup> 2'OMeGp <sub>4</sub> G	OMe	OH	2
m <sup>7</sup> 2'dGp <sub>4</sub> G	H	OH	2
m <sup>7</sup> 3'OMeGp <sub>5</sub> G	OH	OMe	3

**Scheme 1.** Synthesis of dinucleoside P<sup>1</sup>, P<sup>3</sup>-tri-, P<sup>1</sup>, P<sup>4</sup>-tetra- and P<sup>1</sup>, P<sup>5</sup>-pentaphosphates in coupling reaction catalyzed by ZnCl<sub>2</sub>.

ARCA-capped transcripts was 2-fold higher than for the m<sup>7</sup> GpppG-capped transcripts,<sup>[7]</sup> what renders the ARCA containing RNA transcripts very promising in many areas of gene expression research. We present here the synthesis of a new series of dinucleoside tri-, tetra- and pentaphosphates with modifications at 2' and 3' positions of 7-methylguanosine.

## RESULTS

3'-Deoxyguanosine (purchased from Sigma-Aldrich), 2'-O- and 3'-O-methylguanosine obtained as described earlier<sup>[8]</sup> and 2'-deoxyguanosine 5'-monophosphate (from Calbiochem) were the starting compounds for the synthesis of ribose-modified 7-methylguanosine 5'-diphosphate, the key intermediate in preparation of cap analogues. 3'-O-Methylguanosine-, 2'-O-methylguanosine- and 3'-deoxyguanosine 5'-monophosphates were prepared according to the standard Yoshikawa's phosphorylation.<sup>[9]</sup> Monophosphates were converted into diphosphates in a two-step procedure that comprised preparation of nucleoside 5'-monophosphate imidazolides<sup>[10]</sup> and their reaction with triethylammonium phosphate.<sup>[7]</sup> Diphosphates of the modified guanosine nucleosides were methylated with methyl iodide in DMSO.<sup>[11]</sup> The crucial step in the synthesis of the dinucleotide 5', 5'-tri-, tetra- and pentaphosphates was coupling of ribose-modified 7-methylguanosine 5'-diphosphates with the corresponding imidazolidine of guanosine 5'-phosphates.<sup>[7]</sup> The coupling reaction was carried out in dimethylformamide, in the presence of ZnCl<sub>2</sub> as a catalyst.<sup>[12]</sup> These reaction conditions improved significantly the coupling efficiency and allowed to avoid decomposition of the unstable imidazolides. Imidazolides of the guanosine 5'-mono-, di- and triphosphates were prepared by condensation of GMP, GDP and GTP, respectively, with imidazole, using 2,2'-dithiodipyridine and triphenylphosphine as a condensing agent.<sup>[10]</sup>

## ACKNOWLEDGMENTS

This work was supported by KBN 6 P04A 055 17 and PBZ-KBN-059/T09/10/2001.

## REFERENCES

1. Furuichi, Y.; Shatkin, A.J. *Adv. Virus Res.* **2000**, *55*, 135–184.
2. Gingras, A.C.; Raught, B.; Sonenberg, N. *Annu. Rev. Biochem.* **1999**, *68*, 913–963.
3. Cai, A.; Jankowska-Anyszka, M.; Centers, A.; Chlebicka, L.; Stepinski, J.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R.E. *Biochemistry* **1999**, *38*, 8538–8547.
4. Konarska, M.M.; Padgett, R.A.; Sharp, P.A. *Cell* **1984**, *38*, 731–736.
5. Lewis, J.D.; Izaurralde, E. *Eur. J. Biochem.* **1997**, *247*, 461–469.
6. Pasquinelli, A.E.; Dahlberg, J.E.; Lund, E. *RNA* **1995**, *1*, 957–967.



7. Stepinski, J.; Waddell, C.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R.E. *RNA* **2001**, *7*, 1486–1495.
8. Kusmerek, J.; Shugar, D. *Nucleic Acid Res.* **1978**, *4*, s73–s77, Special Publ.
9. Yoshikawa, M.; Kato, T.; Takenishi, T. *Tetrahedron Lett.* **1967**, *8*, 5065–5068.
10. Lohrmann, R.; Orgel, L.E. *Tetrahedron* **1978**, *34*, 853–855.
11. Darzynkiewicz, E.; Ekiel, I.; Tahara, S.M.; Seliger, L.S.; Shatkin, A.J. *Biochemistry* **1985**, *24*, 1701–1707.
12. Kadokura, M.; Wada, T.; Urashima, C.; Sekine, M. *Tetrahedron Lett.* **1997**, *38*, 8359–8362.

